Clinical trials: Enoxaparin
Acute Coronary Syndrome, Factor X
Comparison of Anti-Xa Activity of ENOXA ® Versus LOVENOX ® in Acute Coronary Syndrome
This study is a clinical trial monocentric, open, randomized ENOXA ® versus LOVENOX ®, conducted on two parallel groups of patients admitted in emergency for acute coronary syndrome.
- Trial name
- AXA (NCT01687491)
- Testing
- ENOXA®, LOVENOX®
- Where
- Tunisia
- Volunteers
- 179 people
- Sponsor
- Les Laboratoires des Médicaments Stériles
Venous Thromboembolism
Dose Ranging Study in Elective Total Hip Replacement Surgery
The primary objective is to: demonstrate the efficacy of SR123781A in the prevention of venous thromboembolism (VTE) by the demonstration of a dose-response in patients undergoing total hip replacement surgery.
- Trial name
- DRIVE (NCT00338897)
- Testing
- SR123781A
- Where
- 14 sites in Argentina, Bulgaria and 12 more
- Volunteers
- 1,090 people
- Sponsor
- Sanofi
Non ST Segment Elevation Myocardial Infarction, Unstable Angina
Patients With High-risk Acute Coronary Syndrome Without ST-segment Elevation
This non-inferiority study aims at comparing Versa® to the reference enoxaparin (Clexane®, Sanofi-Aventis) in patients with high-risk unstable angina and NSTEMI.
- Trial name
- VECOR (NCT01356992)
- Testing
- Enoxaparin
- Where
- 5 sites in Brazil
- Volunteers
- 62 people
- Sponsor
- Eurofarma Laboratorios S.A.
Venous Thromboembolism
Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin
The purpose of this study is to assess if 10 mg BAY 59-7939, taken once daily as a tablet, is safe and prevent blood clot which may form after total hip replacement operation.
- Trial name
- NCT00329628
- Testing
- Rivaroxaban (BAY59-7939), Enoxaparin
- Where
- 215 sites in United States, Argentina and 26 more
- Volunteers
- 4,541 people
- Sponsor
- Bayer
Thrombosis, Venous
Hemorrhage Risk Prescribed Arixtra
Arixtra (fondaparinux sodium) was the first selective Factor Xa inhibitor to be marketed. As with all anticoagulants, an important adverse event associated with Arixtra use is haemorrhage.
- Trial name
- NCT01064362
- Testing
- Fondaparinux sodium, Low molecular weight heparin (LMWH)
- Volunteers
- 13,442 people
- Sponsor
- GlaxoSmithKline
Embolism, Thrombosis
Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach
Objectives are to evaluate whether idrabiotaparinux sodium (SSR126517E) is as least as effective as a standard warfarin treatment to prevent recurrence of venous thromboembolic events (VTE) in patients with symptomatic pulmonary…
- Trial name
- CASSIOPEA (NCT00345618)
- Testing
- Idrabiotaparinux sodium, Warfarin, Avidin
- Where
- 38 sites in United States, Argentina and 36 more
- Volunteers
- 3,202 people
- Sponsor
- Sanofi
Venous Thromboembolism
Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty
The primary objective of the trial is to demonstrate non-inferiority of 220 mg oral dabigatran etexilate compared to 40 mg subcutaneous enoxaparin administered once daily.
- Trial name
- NCT00657150
- Testing
- Enoxaparin, Dabigatran etexilate
- Where
- 108 sites in United States, Australia and 17 more
- Volunteers
- 2,055 people
- Sponsor
- Boehringer Ingelheim
Venous Thromboembolism
Active Comparator-Controlled Study to Assess Safety and Efficacy of ISIS-FXIRx in Total Knee Arthroplasty
The purpose of this study is: To assess the safety and efficacy profile of ISIS-FXIRx, including incidence of bleeding and VTE, in patients undergoing total knee arthroplasty.
- Trial name
- NCT01713361
- Testing
- ISIS-FXIRx Dose #2, ISIS-FXIRx Dose #3, Enoxaparin
- Where
- 21 sites in Bulgaria, Canada and 3 more
- Volunteers
- 315 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Thromboembolism, Arthroplasty, Replacement, Hip
Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery
The objective of this study is to determine the comparative efficacy and safety of two oral regimens of dabigatran etexilate, compared to a standard subcutaneous regimen of enoxaparin, in prevention of venous thromboembolism in…
- Trial name
- NCT00168818
- Testing
- dabigatran etexilate, enoxaparin
- Where
- 116 sites in Australia, Austria and 14 more
- Volunteers
- 3,494 people
- Sponsor
- Boehringer Ingelheim
Thromboembolism
Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events
This study is being carried out to study the efficacy and safety of treatment with melagatran injection followed by ximelagatran tablets in preventing blood clots, compared with enoxaparin for a period of 5-6 weeks.
- Trial name
- EXTEND (NCT00206089)
- Testing
- EXANTA
- Where
- 125 sites in Austria, Belgium and 14 more
- Volunteers
- 3,300 people
- Sponsor
- AstraZeneca
Venous Thromboembolism, Arthroplasty, Replacement, Hip
A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery
The purpose of this study is to evaluate the efficacy and safety of various doses of YM150 (the experimental drug) compared to enoxaparin in the prevention of venous thromboembolism in patients that are undergoing elective hip…
- Trial name
- ONYX-3 (NCT00902928)
- Testing
- YM150, enoxaparin
- Where
- 156 sites in United States, Australia and 26 more
- Volunteers
- 1,992 people
- Sponsor
- Astellas Pharma Europe B.V.
Venous Thromboembolism
Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients
This study will evaluate if extended therapy with oral rivaroxaban can prevent blood clots in the leg and lung that can occur with patients hospitalized for acute medical illness, and compare these results with those of the…
- Trial name
- MAGELLAN (NCT00571649)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin
- Where
- 676 sites in United States, Argentina and 51 more
- Volunteers
- 8,101 people
- Sponsor
- Bayer
Thromboembolism, Prevention
ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial
Patients undergoing surgery, especially hip and knee surgery, are at high risk for VTE (up to 60 % without prophylaxis). The administration of drugs for thromboprophylaxis, such as heparins, significantly lowers that risk, but…
- Trial name
- ODiXaHip (NCT00839826)
- Testing
- Rivaroxaban (BAY59-7939), Enoxaparin
- Where
- 41 sites in Austria, Belgium and 9 more
- Volunteers
- 641 people
- Sponsor
- Bayer
Hemodialysis
HENOX: Enoxaparine in Hemodialysis
Primary objective: To assess clinical efficacy of single bolus anticoagulation with Enoxaparin in chronic hemodialysis Secondary objective: To assess safety and tolerability by the number of spontaneously reported adverse events…
- Trial name
- NCT00347490
- Testing
- Enoxaparine
- Where
- Thailand
- Volunteers
- 100 people
- Sponsor
- Sanofi
Venous Thromboembolism
Prophylactic Use of Sodium Enoxaparin for Venous Thromboembolism in High-Risk Abdominal Surgery
The purpose of this study is to compare the safety and security and efficacy of sodium enoxaparin Cristália Produtos Químicos Farmaceuticos Ltda - Endocris with Clexane (Sanofi-Aventis) to prevent Venous Thromboembolism in…
- Trial name
- NCT01308528
- Testing
- Sodium enoxaparin, Sodium Enoxaparin clexane
- Where
- 9 sites in Brazil
- Volunteers
- 243 people
- Sponsor
- Cristália Produtos Químicos Farmacêuticos Ltda.
Unstable Angina, Myocardial Infarction
SYNERGY: Open Study of Enoxaparin Versus Unfractionated Heparin in Patients With Acute Coronary Syndromes
Patients experiencing a mild heart attack will receive one of two medications which thin the blood to discern which is superior.
- Conditions
- Unstable Angina, Myocardial Infarction, Myocardial Ischemia
- Trial name
- NCT00043784
- Testing
- enoxaparin
- Where
- United States
- Volunteers
- 8,000 people
- Sponsor
- Sanofi
Venous Thromboembolism
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery
The primary objective was to demonstrate the dose-response of Semuloparin sodium (AVE5026) for the prevention of Venous Thromboembolism [VTE] in patients undergoing total knee replacement [TKR] surgery.
- Trial name
- TREK (NCT00331838)
- Testing
- Semuloparin sodium, Enoxaparin sodium
- Where
- 19 sites in Argentina, Bulgaria and 17 more
- Volunteers
- 705 people
- Sponsor
- Sanofi
Venous Thromboembolism
Study to Assess the Safety and Efficacy of SelK2 to Prevent Blood Clots in Patients Undergoing Total Knee Replacement
The main purpose of this study is to determine if an investigational medication called SelK2 works in preventing a condition called "venous thromboembolism" (VTE) in patients having a total knee replacement.
- Trial name
- COURSE (NCT03812328)
- Testing
- SelK2, Enoxaparin
- Where
- 21 sites in Bulgaria, Latvia and 3 more
- Volunteers
- 207 people
- Sponsor
- Tetherex Pharmaceuticals Corporation
Thrombosis
A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation
To investigate the safety and pharmacokinetics of apixaban in children with congenital or acquired heart disease who have a need for anticoagulation.
- Trial name
- NCT02981472
- Testing
- Apixaban, Vitamin K Antagonist (VKA), Low Molecular Weight Heparin (LMWH)
- Where
- 46 sites in United States, Argentina and 12 more
- Volunteers
- 192 people
- Sponsor
- Bristol-Myers Squibb
Venous Thromboembolism
Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement
The purpose of this study is to determine if TAK-442, once daily (QD) or twice daily (BID), is as safe and effective as enoxaparin in preventing the development of blood clots after knee replacement surgery.
- Trial name
- NCT00641732
- Testing
- TAK-442, Enoxaparin
- Where
- 64 sites in United States, Canada
- Volunteers
- 1,045 people
- Sponsor
- Takeda